Cryptogenic sensory polyneuropathy

Neurologic Clinics

Volumn 31, Issue 2, 2013, Pages 463-476

  Pasnoor, Mamatha ^a   Dimachkie, Mazen M ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic sensory sensorimotor polyneuropathy; Idiopathic neuropathy; Neuropathic pain; Polyneuropathy

Indexed keywords

CANNABINOID; CAPSAICIN; CARBAMAZEPINE; CLONIDINE; CYANOCOBALAMIN; DEXTROMETHORPHAN; DULOXETINE; GLUCOSE; HOMOCYSTEINE; LAMOTRIGINE; MEMANTINE; METHYLMALONIC ACID; MEXILETINE; PREGABALIN; TOPIRAMATE; VALPROIC ACID;

AGE DISTRIBUTION; BRAIN ELECTROPHYSIOLOGY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CYANOCOBALAMIN DEFICIENCY; CYRPTOGENIC SENSORY POLYNEUROPATHY; DISEASE COURSE; ELECTROMYOGRAPHY; FAMILY HISTORY; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; INCIDENCE; LUMBAR PUNCTURE; NERVE BIOPSY; NERVE CONDUCTION; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PHENOTYPE; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; REVIEW; SENSORY DYSFUNCTION; SEROLOGY; SKIN BIOPSY; VITAMIN BLOOD LEVEL; WEAKNESS;

AGED, 80 AND OVER; ELECTRODIAGNOSIS; GENETIC TESTING; HUMANS; MALE; NEURAL CONDUCTION; PAIN MANAGEMENT; POLYNEUROPATHIES; SENSATION DISORDERS;

EID: 84877137375     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.01.008     Document Type: Review

References (72)

1. Beghi E., Monticelli M.L. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). Neurology 1995, 45(10):1832-1836.
2. Wolfe G.I., Baker N.S., Amato A.A., et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol 1999, 56(5):540-547.
3. Matthews W.B. Cryptogenic polyneuritis. Proc R Soc Med 1952, 45:667-669.
4. Rose F.C. Peripheral neuropathy. Proc R Soc Med 1960, 53:51-53.
5. Fagius J. Chronic cryptogenic polyneuropathy: the search for a cause. Acta Neurol Scand 1983, 67:173-180.
6. König F., Neundörfer B., Kömpf D. Polyneuropathies in old age. Dtsch Med Wochenschr 1984, 109(19):735-737.
7. McLeod J.G., Tuck R.R., Pollard J.D., et al. Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry 1984, 47:530-535.
8. Grahmann F., Winterholler M., Neundörfer B. Cryptogenic polyneuropathies: an out-patient follow-up study. Acta Neurol Scand 1991, 84:221-225.
9. Hopf H.C., Althaus H.H., Vogel P. An evaluation of the course of peripheral neuropathies based on clinical and neurographical re-examinations. Eur Neurol 1973, 9:90-104.
10. Corvisier N., Vallat J.M., Hugon J., et al. Les neuropathies de cause indéterminée. Rev Neurol (Paris) 1987, 143:279-283.
11. Notermans N.C., Wokke J.H., Franssen H., et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993, 56:1066-1071.
12. Jann S., Beretta S., Bramerio M., et al. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle Nerve 2001, 24(9):1197-1201.
13. De Sousa E.A., Hays A.P., Chin R.L., et al. Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. J Neurol Neurosurg Psychiatry 2006, 77(8):983-985.
14. Khan S., Wolfe G., Nascimento O., et al. North American and South America (NA-SA) Neuropathy project. Neurology 2006, 66:A84. [abstract].
15. Pasnoor M., Nascimento O., Trivedi J. North America and South America (NA-SA) Neuropathy Project. Submitted to International Journal of Neuroscience 2013.
16. Dyck P.J., Oviatt K.F., Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981, 10(3):222-226.
17. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72(2):185-192.
18. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72(2):177-184.
19. Notermans N.C., Wokke J.H., van der Graaf Y., et al. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry 1994, 57(12):1525-1527.
20. Periquet M.I., Novak V., Collins M.P., et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology 1999, 53(8):1641-1647.
21. Hughes R.A., Umapathi T., Gray I.A., et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004, 127(Pt 8):1723-1730.
22. Lindh J., Tondel M., Osterberg A., et al. Cryptogenic polyneuropathy: clinical and neurophysiological findings. J Peripher Nerv Syst 2005, 10(1):31-37.
23. Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl 1970, 44:3-72.
24. Gorson K.C., Ropper A.H. Idiopathic distal small fiber neuropathy. Acta Neurol Scand 1995, 92(5):376-382.
25. Barohn R.J. Approach to peripheral neuropathy and neuronopathy. Semin Neurol 1998, 18(1):7-18.
26. Saperstein D.S., Wolfe G.I., Gronseth G.S., et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 2003, 60(9):1296-1301.
27. Allen R.H., Stabler S.P., Savage D.G., et al. Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol 1990, 34(2):90-98.
28. Savage D.G., Lindenbaum J., Stabler S.P., et al. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994, 96(3):239-246.
29. Kyle R.A. 'Benign' monoclonal gammopathy. A misnomer. JAMA 1984, 251(14):1849-1854.
30. Bosch E.P., Smith B.E. Peripheral neuropathies associated with monoclonal proteins. Med Clin North Am 1993, 77(1):125-139.
31. Kissel J.T., Mendell J.R. Neuropathies associated with monoclonal gammopathies. Neuromuscul Disord 1996, 6(1):3-18.
32. Ropper A.H., Gorson K.C. Neuropathies associated with paraproteinemia. N Engl J Med 1998, 338(22):1601-1607.
33. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995, 37(Suppl 1):S32-S42.
34. Notermans N.C., Wokke J.H., Lokhorst H.M., et al. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994, 117(Pt 6):1385-1393.
35. Notermans N.C., Wokke J.H., van den Berg L.H., et al. Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy. Brain 1996, 119(Pt 2):421-427.
36. Pestronk A., Li F., Griffin J., et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991, 41(3):357-362.
37. Nemni R., Fazio R., Quattrini A., et al. Antibodies to sulfatide and to chondroitin sulfate C in patients with chronic sensory neuropathy. J Neuroimmunol 1993, 43(1-2):79-85.
38. Klein C.J., Lennon V.A., Aston P.A., et al. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012, 79(11):1136-1144. Epub 2012 Aug 15. 10.1212/WNL.0b013e3182698cab.
39. Sandroni P., Vernino S., Klein C.M., et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 2004, 61(1):44-48.
40. Koike H., Watanabe H., Sobue G. The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 2013, 84(1):98-106. Epub 2012 Aug 20. 10.1136/jnnp-2012-302833.
41. Wise C.A., Garcia C.A., Davis S.N., et al. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet 1993, 53(4):853-863.
42. Nelis E., Van Broeckhoven C., De Jonghe P., et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996, 4(1):25-33.
43. Leonardis L., Zidar J., Ekici A., et al. Autosomal dominant Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies: detection of the recombination in Slovene patients and exclusion of the potentially recessive Thr118Met PMP22 point mutation. Int J Mol Med 1998, 1(2):495-501.
44. Choi B.O., Lee M.S., Shin S.H., et al. Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2004, 24(2):185-186.
45. Faber C.G., Hoeijmakers J.G., Ahn H.S., et al. Gain of function Na1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012, 71(1):26-29. Epub 2011 Jun 22. 10.1002/ana.22485.
46. Schecht H.M., Olney R.K. Clinically sensory distal axonal polyneuropathy: early motor involvement. Electroencephalogr Clin Neurophysiol 1996, 98(3):26P.
47. Vrancken A.F., Franssen H., Wokke J.H., et al. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Arch Neurol 2002, 59(4):533-540.
48. Holland N.R., Crawford T.O., Hauer P., et al. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol 1998, 44(1):47-59.
49. Gruener G., Dyck P.J. Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol 1994, 11(6):568-583.
50. Finnerup N.B., Johannesen I.L., Fuglsang-Frederiksen A., et al. Sensory function in spinal cord injury patients with and without central pain. Brain 2003, 126(Pt 1):57-70.
51. Freeman R., Chase K.P., Risk M.R. Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy. Neurology 2003, 60(3):465-470.
52. Geber C., Klein T., Azad S., et al. Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study. Pain 2011, 152(3):548-556.
53. Shy M.E., Frohman E.M., So Y.T., et al. Therapeutics and technology assessment subcommittee of the American academy of neurology. Quantitative sensory testing: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2003, 60(6):898-904.
54. Chin R.L., Latov N., Sander H.W., et al. Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J Peripher Nerv Syst 2004, 9(3):132-137.
55. McArthur J.C., Stocks E.A., Hauer P., et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998, 55(12):1513-1520.
56. Devigili G., Tugnoli V., Penza P., et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008, 131(Pt 7):1912-1925.
57. Walk D., Wendelschafer-Crabb G., Davey C., et al. Concordance between epidermal nerve fiber density and sensory examination in patients with symptoms of idiopathic small fiber neuropathy. J Neurol Sci 2007, 255(1-2):23-26.
58. Herrmann D.N., Griffin J.W., Hauer P., et al. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 1999, 53(8):1634-1640.
59. Lauria G., Cornblath D.R., Johansson O., et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005, 12(10):747-758.
60. Pasnoor M., Herbelin L., Johnson M., et al. Clinical electrophysiologic and skin biopsy findings in cryptogenic sensorimotor polyneuropathy compared to diabetic polyneuropathy and normal controls. Neurology 2009, 72(Suppl 3):A217. [abstract].
61. Teunissen L.L., Notermans N.C., Franssen H., et al. Differences between hereditary motor and sensory neuropathy type 2 and chronic idiopathic axonal neuropathy. A clinical and electrophysiological study. Brain 1997, 120(Pt 6):955-962.
62. Mittal M., Pasnoor M., Mummaneni R.B., et al. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. Int J Neurosci 2011, 121(9):521-527.
63. Attal N., Cruccu G., Haanpaa M., et al. EFNS guidelines on the pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13(11):1153-1169.
64. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132(3):237-251.
65. Moulin D.E., Clark A.J., Gilron I., et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12(1):13-21.
66. O'Connor A.B., Dworkin R.H. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009, 122(Suppl 10):S22-S32.
67. Gilron I., Bailey J.M., Tu D., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352(13):1324-1334.
68. Bril V., England J., Franklin G.M., et al. Evidence-based guideline: treatment of painful diabetic peripheral neuropathy. Neurology 2011, 76:1758-1765.
69. Slogosky S.L., Chavin J.M., Heiman-Patterson T., et al. Idiopathic axonal neuropathy responsive to immunosuppression. Ann Neurol 1995, 38:336. [abstract].
70. Donofrio P.D., Berger A., Brannagan T.H., et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009, 40(5):890-900.
71. Richardson J.K. Factors associated with falls in older patients with diffuse polyneuropathy. J Am Geriatr Soc 2002, 50(11):1767-1773.
72. Tofthagen C., Visovsky C., Berry D.L. Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum 2012, 39(5):E416-E424.